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Ouraimistoinvestigatetheelevationofmatrixproteinsintissuesobtainedfromdistal,abovethesinotubularjunction(proximal),
concave, and convex sites of aneurysms in the ascending aorta using a simultaneous multiplex protein detection system. Tissues
were collected from 41 patients with ascending aortic aneurysms. A total of 31 patients had a bicuspid aortic valve (BAV), whereas
10 had a tricuspid aortic valve (TAV). Concave and convex aortic site samples were collected from all patients, whereas proximal
and distal convexity samples were obtained from 19 patients with BAV and 7 patients with TAV. Simultaneous detection of matrix
metalloproteinases (MMPs) and their inhibitors (TIMPs) was performed at each of the four aortic sites. MMP-2 levels were higher
in the concave aortic sites than in the convex aortic sites. In contrast, MMP-8 levels were higher in the convex sites than in the
concave sites, as were MMP-9 levels. In both BAV and TAV patients, TIMP-3 levels were higher in the concave sites than in the
convex sites. However, TIMP-2 and TIMP-4 levels were signiﬁcantly elevated in the sinotubular proximal aorta of BAV patients.
Simultaneous detection of MMPs and TIMPs revealed diﬀe r e n tl e v e l sa td i ﬀerent aortic sites in the same patient.
1.Introduction
Aortic aneurysms are characterized by weakened and dis-
torted arterial architecture and are relatively common causes
of death because of arterial dissection or rupture. These an-
eurysms are common among the elderly. A bicuspid aortic
valve (BAV), the most common congenital cardiac malfor-
mation, is associated with ascending thoracic aneurysms and
appears to reﬂect a common developmental defect [1, 2].
Both cellular and extracellular processes are involved in the
pathogenesis of ascending thoracic aortic aneurysms in pa-
tients with BAV [3–6]. On an average, patients with BAV un-
dergo surgery to correct abnormal valve morphology and/or
to treat complications associated with the diseased aortic
valve a decade earlier than patients with a normal tricuspid
aortic valve. Replacing the aortic valve in patients with BAV
does not prevent progressive dilation of the aortic root and
ascending aorta [7].
Manystudieshavedemonstratedabnormalitiesinmatrix
metalloproteinases (MMPs) and tissue inhibitors of metal-
loproteinases (TIMPs) in aneurysmal tissues [8–10]. Using
tissue microarray techniques, Koullias et al. [10]d e t e c t e d
signiﬁcantly higher levels of MMP-2 and MMP-9 in BAVs
than in TAVs; in this study, MMP-2, MMP-9, and TIMP-1
levelsweresigniﬁcantlyhigherinBAVtissuesthaninallother
tissues (control and TAV tissues). Lemaire et al. [11]f o u n d
a lack of inﬂammatory activity, an increased level of MMP-
2, and normal expression of MMP-9, TIMP-1, and TIMP-2
in aneurysmal tissues obtained from patients with BAV. In2 The Scientiﬁc World Journal
contrast, in aneurysmal tissues obtained from patients with
TAV, they found increased inﬂammatory activity and MMP-
9l e v e l s[ 11]. They also demonstrated an increased incidence
of cultured vascular smooth muscle cell (VSMC) loss among
individuals with BAV and Marfan’s syndrome (MFS) when
compared with that in healthy controls and suggested a pos-
sible link between MMP-2 upregulation and VSMC apopto-
sis in MFS. There are certainly similarities in the histology
of aneurysmal aorta tissues in MFS and BAV patients [8].
In MFS, a mutation in the gene for the extracellular matrix
protein, ﬁbrillin-1, leads to dysregulation of transforming
growth factor beta signaling [12]. Although many studies
have demonstrated MMP elevation in aneurysms, matrix
protein expression appears to vary between aneurysmal
tissues [13].
This study aimed to identify the matrix proteins present
at diﬀerent sites in aortic aneurysms. A system for simul-
taneously detecting six MMPs and their four inhibitors at
diﬀerent sites in the thoracic aorta was developed. This
method is as accurate as older methods, the advantage being
that it minimizes the errors associated with those methods.
2.MaterialsandMethods
2.1. Study Protocol. The study protocol was approved by
the Institutional Ethics Committee, and written informed
consent of each patient was obtained. In cases of ascending
aorta replacement surgery, 3 × 3mm distal specimens were
obtained for protein multiplex analysis from four diﬀerent
sites of ascending aortic aneurysms: concave, convex, distal,
and proximal aortic sites (Figure 1). The 3 × 3mm speci-
menswerethenwashedinwashbuﬀer,transferredtoBioplex
cell lysis buﬀer (BioRad Laboratories, Hercules, CA, USA),
and frozen in liquid nitrogen. Specimens were stored at
−80◦C until further use. Patient demographics are shown in
Table 1.
2.2. Tissue Preparation for the Multiplex Method. Tissue
samples were thawed in 500μL lysis solution and ground
with an Ultra-turrax T8 homogenizer (IKA Labortechnik,
Staufen, Germany). After about 20 strokes, the debris and
lysateswereseparatedbycentrifugationat4500×gfor5min.
The supernatant was immediately processed to measure the
amount of protein, MMPs, and TIMPs. The samples were
kept on ice during all procedures to avoid protein denatu-
ration.
The multiplex method used color-coded bead sets conju-
gated with speciﬁc reactants, each of which was speciﬁc for a
diﬀerent target molecule. The principle is that of a capture
sandwich (immuno)-assay, but 96-well microtiter plates
with ﬁlter bottoms are used. Antibodies speciﬁcally directed
against the analytes (MMPs and TIMPs) of interest were
covalently bound to color-coded 5.6μmp o l y s t y r e n eb e a d s
and mixed with a deﬁned sample volume containing equal
amounts of total protein but an unknown amount of MMPs
and TIMPs. A standard curve was obtained for each run by
dilutingofastandardcocktaildesignedfordiﬀerentpanelsof
targets provided by the manufacturer (BioRad Laboratories,
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Figure 1: Schematic representation of ascending aneurysms. Re-
sected tissue from the distal, convex, proximal, and concave aortic
sites used for the analysis. Overall detection of MMPs and TIMPs at
the concave and convex aortic sites.
Hercules, CA, USA). After three wash cycles to remove
unbound protein (via a vacuum manifold through the plate’s
ﬁlter bottom), biotinylated detection antibodies speciﬁc for
a second epitope of the analytes were added. The mixtures
were then washed another three times and streptavidin
phycoerythrin (S-PE) added for speciﬁc binding to biotin.
The mixture in each well was then drawn up into a dual-
laser, ﬂow-based luminometer using Luminex technology
(Bioplex, BioRad Laboratories, Hercules, CA, USA). Brieﬂy,
one laser identiﬁed the color-coded beads and sorted the
targetswhiletheotherlaserdeterminedthemagnitudeofthe
S-PE value, which was directly proportional to the amount
of analyte (MMP or TIMP). MMP-1, MMP-2, MMP-8,
MMP-9, MMP-12, and MMP-13 as well as TIMP-1, TIMP-
2, TIMP-3, and TIMP-4 were detected using a Human
MMP Fluorokine MultiAnalyte Proﬁling (FMAP) Base Kit
and other appropriate kits for this panel of targets from
R&D Systems (Minneapolis, MN, USA); all were applied in
accordance with the manufacturer’s instructions.
2.3. Statistics. A l ld a t ae x a m i n e da r ee x p r e s s e da sm e a n±
standard error mean or standard deviation. Statistical analy-
sis of the data was performed using Excel/WinSTAT software
(R. Fitch software, Bad Krozingen, Germany). Diﬀerences
amonggroupswereassessedwithWilcoxontests,followedby
a Mann-Whitney U test. Signiﬁcant diﬀerences were deﬁned
by P<0.05.The Scientiﬁc World Journal 3
Table 1: Patient demographics and clinical characteristics.
N Age (Y) Sex (M/F) A. Ømm AVS AVI AV com.
All 41 53.9 ± 13.1 31/10 53.7 ± 5.6 3 20 18
BAV 31 50.9 ± 13.1 24/7 52.7 ± 4.9 3 10 18
TAV 10 63.2 ± 8.2 7/3 56.7 ± 6.6 0 10 0
Absolute values (±SD): A. Ømm: ascending aorta in mm: AVS: aortic valve stenosis: AVI: aortic valve insuﬃciency: AV com.: aortic valve combined.
Table 2: Overall detection of MMPs and TIMPs using the multiplex system.
N = 41 N = 41
P
Concave Average (pg/mL) SD± Convex Average (pg/mL) SD±
MMP-1 0.004 0.018 MMP-1 0.005 0.028 n.s.
MMP-2 118.536 61.232 MMP-2 96.035 47.555 0.04
MMP-8 2.760 5.147 MMP-8 7.056 10.626 0.001
MMP-9 8.923 13.249 MMP-9 18.279 28.544 0.007
TIMP-1 107.840 265.137 TIMP-1 73.168 112.832 n.s.
TIMP-2 128.211 59.117 TIMP-2 133.354 42.847 n.s.
TIMP-3 10.417 3.413 TIMP-3 8.810 5.028 0.0007
TIMP-4 0.216 0.084 TIMP-4 0.207 0.091 n.s.
n.s.:not signiﬁcant.
3. Results
3.1. Study Subjects. A total of 41 patients were included in
the analysis; concave and convex aortic site samples were
collected from all patients, whereas proximal and distal
convexity samples were obtained from 19 patients with BAV
and 7 patients with TAV. The BAV group of 31 patients
comprised 24 males (77%) and 7 females, while 7 of the
10 TAV patients were male (70%). The age distribution was
considerably diﬀerent between the two groups. BAV patients
had a mean age of 50.9 ± 12.9 years and were signiﬁcantly
younger than the TAV patients, whose mean age was 63.2 ±
8.2y e a r s( P = 0.006). The mean aortic diameter was, how-
ever, comparable between the groups (52.7 ± 4.9mmversus
56.7 ± 6.6mm). There were also diﬀerences in the type
of aortic valve disease identiﬁed between the two groups.
While the BAV group included 10 patients with aortic valve
insuﬃciency (32%), 3 patients with stenosis (10%), and 18
patients with a combination of both (58%), all TAV patients
suﬀered from aortic valve insuﬃciency.
3.2. Simultaneous Detection of MMPs and TIMPs Using Mul-
tiplex System Analyses. Multiplex system (Bio-Plex) analyses
were used to determine protein concentrations of MMP-1,
MMP-2, MMP-8, MMP-9, MMP-12, and MMP-13 as well as
concentrations of TIMP-1, TIMP-2, TIMP-3, and TIMP-4 at
diﬀerent sites of an aneurysmatic aorta ascendens (Figure 1).
Resultswereanalyzedinbothpatientgroupsaccordingtothe
following classiﬁcations:
(a) areas 1 (the concave aortic site) and 23II (the convex
aortic site),
(b) areas 1 and 23I (the distal aorta) and 23III (the prox-
imal aorta),
(c) areas 23I and 23II, 23II and 23III, and 23I and 23III,
(d) comparison between every site in both BAV and TAV
patients.
Analyses were carried out simultaneously for all MMPs
and TIMPs. Subsequently, the patients were divided into
diﬀerent groups on the basis of age, diameter of aneurysm,
sex, and aortic valve disease. The above categories (a), (b),
(c), and (d) were used to compare these groups. The groups
were also compared with each other (e).
MMP-1, MMP-12, and MMP-13 were undetectable in
most cases because of very low concentrations. Therefore,
they were omitted from the ﬁnal calculations.
Comparison (41 patients) between areas 1 and 23II
revealed signiﬁcantly higher levels of MMP-8 and MMP-9 in
area 23II, a dilated aortic site, than in area 1 in all patients
(P = 0.001, P = 0.007). MMP-2 and TIMP-3 levels, however,
were higher in area 1 (P = 0.04, P = 0.0007; Table 2).
3.3. Detection of MMPs and TIMPs in BAV versus TAV
Patients (Concave, Distal, and Proximal Aortic Sites). For
patients with BAV, the aneurysmal areas 23I and 23III
had signiﬁcantly higher MMP-8 and MMP-9 concentrations
(MMP-8: P = 0.003, P = 0.02; MMP-9: P = 0.01, P = 0.04)
than those in area 1, whereas TIMP-3 levels were higher in
area 1 (P = 0.004 versus area 23I, P = 0.03 versus area
23III).
TAVpatientshadhigherTIMP-3levelsinnondilatedarea
1 than in the dilated area 23II (P = 0.008). When areas 23I,
23II, and 23III were compared, the BAV group was found to
havesigniﬁcantlyhigherTIMP-3levelsthanthoseintheTAV
group (P = 0.02).4 The Scientiﬁc World Journal
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Figure 2: Detection of MMPs and TIMPs in BAV and TAV patients
with aneurysms ≤54 mm in diameter.
3.4. Cross-comparisons between the BAV and TAV Groups
3.4.1. Elevation of MMPs and TIMPs Based on the Diameter
of the Aortic Aneurysm. To classify patients on the basis of
the aortic aneurysm diameter, a threshold diameter between
54mm and 55mm was chosen after considering that the
mean diameter was 53.7 ± 5.6mm. Most TAV-associated
aneurysms had larger diameters than the BAV-associated
aneurysms. Therefore, all TAV patients were in the group
with aneurysms ≥55mm.
When area 1 and area 23II were compared in all patients
with an aneurysm of ≤54mm diameter (n = 23), higher
M M P - 8a n dM M P - 9l e v e l sw e r eo b s e r v e di na r e a2 3 I It h a n
in area 1. On the other hand, expressions of TIMP-3 and
TIMP-4 were signiﬁcantly lower in area 23II than in area 1
(P = 0.002; P = 0.002; Figure 2).
Patients with an aneurysm ≥55mm in diameter (n =
18) had considerably higher MMP-8 and MMP-9 levels in
aneurysmal area 23II than in area 1 (P = 0.01; P = 0.04)
(Figure 3).
3.4.2. Elevation of MMPs and TIMPs with Advancing Age.
Patients were classiﬁed into two groups according to their
age. Due to the signiﬁcantly higher age of the TAV patients
(63.2 ± 8.2 years), the mean age of the BAV patients (50.9 ±
12.9y e a r s ,P = 0.006) was used as a reference, with 51 years
considered the age threshold. All TAV patients were sorted
into the group aged older than 51 years (Table 3).
Within the BAV group, the patients aged ≤51 years had
signiﬁcantly lower expression of TIMP-3 in the dilated area
23II than in area 1 (10.35 ±3.4pg/mL,P = 0.01).
Results for the TAV group and the comparison between
patients of diﬀerent ages were omitted because of their older
age.
In BAV patients aged ≥52 years, signiﬁcantly elevated
MMP-8 and MMP-9 levels were detected in area 23II when
MMP-1 MMP-2 MMP-8 MMP-9 TIMP-1 TIMP-2 TIMP-3 TIMP-4
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Figure 3: Detection of MMPs and TIMPs in BAV and TAV patients
with aneurysms ≥55 mm in diameter.
compared with those in area 1 (10.84 ± 13.92pg/mL, P =
0.002; 25.45 ±37.84, P = 0.01; Table 4).
When BAV and TAV patients were compared, elevated
TIMP-3 levels were observed in area 23II in BAV patients
(P = 0.02).
3.4.3.ElevationofMMPsandTIMPsBasedonSex. No female
TAV group was established because of the low number of
female patients. Analyses of the male BAV group revealed
signiﬁcantly increased MMP-8 and MMP-9 levels in dilated
a r e a2 3 I It h a ni na r e a1( P = 0.005, P = 0.01), whereas
TIMP-3 concentrations were higher in area 1 (P = 0.03).
Comparisonsbetweenthetwomalegroupsdidnotreveal
any signiﬁcant results.
BecauseofthesmallnumberoffemaleBAVpatients,only
areas 1 and 23II could be compared. These were not signifi-
cantly diﬀerent.
Comparison of male and female BAV patients revealed
signiﬁcantly higher TIMP-1 levels in area 23II of female pa-
tients (P = 0.03).
3.4.4. Elevation of MMPs and TIMPs Based on Aortic Valve
Disease. Classiﬁcation of patients according to the type of
aortic valve disease was restricted by the low number of
patients with isolated stenosis. Therefore, only BAV patients
with aortic valve insuﬃciency or a combination of insuﬃ-
ciency and stenosis were considered.
AllTAVpatientswereincludedintheinsuﬃciencygroup.
The BAV group with aortic valve insuﬃciency had in-
c r e a s e dT I M P - 3l e v e l si na r e a2 3 I It h a ni na r e a1( P = 0.02).
No further comparisons were made because of small sample
number.
BAVpatientswithaorticvalveinsuﬃciencyhadincreased
TIMP-3 levels in aortic area 23II when compared with those
in TAV patients with aortic valve insuﬃciency (P = 0.03).The Scientiﬁc World Journal 5
Table 3: Age diﬀerences and detection of MMPs and TIMPs in BAV and TAV patients aged ≤51 years.
Average
pg/mL
BAV (n = 16) TAV (n = 0)
Concave Convex P Concave Convex P
MMP-1 0.006 ± 0.02 0.01 ± 0.04 n.s. — — —
MMP-2 109.8 ± 59.5 100.3 ± 56.6 n.s. — — —
MMP-8 2.4 ± 4.7 2.3 ± 2.2 n.s. — — —
MMP-9 7.4 ± 10.7 8.7 ± 9.2 n.s. — — —
TIMP-1 52.8 ± 37.8 58.5 ± 64.9 n.s. — — —
TIMP-2 135.0 ± 71.5 125.2 ± 42.3 n.s. — — —
TIMP-3 10.3 ± 3.4 8.2 ± 3.2 0.01 — — —
TIMP-4 0.2 ± 0.08 0.2 ± 0.07 n.s. — — —
n.s.: not signiﬁcant.
Table 4: Age diﬀerences and detection of MMPs and TIMPs in BAV and TAV patients aged ≥52 years.
Average
(pg/mL)
BAV (n = 15) TAV (n = 10)
Concave Convex P Concave Convex P
MMP-1 0.001 ± 0.005 0.000 n.s. 0.005 ± 0.01 0.003 ± 0.006 n.s.
MMP-2 136.2 ± 61.1 104.7 ± 43.8 n.s. 105.7 ± 64.0 76.1 ± 33.1 n.s.
MMP-8 1.7 ± 1.9 10.8 ± 13.9 0.002 4.8 ± 8.2 8.9 ± 11.2 n.s.
MMP-9 6.7 ± 8.1 25.4 ± 37.8 0.01 14.6 ± 20.8 22.7 ± 31.3 n.s.
TIMP-1 201.8 ± 428.7 61.4 ± 30.1 n.s. 54.8 ± 30.7 114.2 ± 213.7 n.s.
TIMP-2 132.3 ± 50.8 141.9 ± 34.2 n.s. 111.1 ± 50.5 133.5 ± 55.6 n.s.
TIMP-3 11.2 ± 3.4 11.0 ± 7.1 n.s. 9.2 ± 3.3 6.4 ± 1.0 0.02
TIMP-4 0.24 ± 0.07 0.24 ± 0.11 n.s. 0.18 ± 0.10 0.16 ± 0.05 n.s.
n.s.: not signiﬁcant.
The BAV group with a combination of insuﬃciency and
stenosis had signiﬁcantly higher MMP-8 and MMP-9 levels
in aneurysmal area 23II than in area 1 (P = 0.004, P =
0.007).
4. Discussion
In the literature, reports of the matrix protein expression in
aneurysmaltissueshavedocumentedvariedresults[8,10,11,
and 13]. In accordance with the published data, we observed
the proﬁles of six MMPs and their four inhibitors using a
simultaneous detection system at four diﬀerent aortic sites
(concave, convex, distal, and proximal sites) of ascend-
ing aortic aneurysms. MMP-2, MMP-8, MMP-9, TIMP-1,
TIMP-2, TIMP-3, and TIMP-4 were all detected and quan-
tiﬁed. However, protein concentrations of MMP-12 and
MMP-13 were very low and therefore omitted. These areas
were combined in 41 patients (31 BAV and 10 TAV). The
patients were divided into groups on the basis of age, as-
cending aneurysm diameter, sex, and valve malformation.
When the entire patient dataset was assessed, signiﬁcantly
higher levels of MMP-8 and MMP-9 were detected in the
dilatedaorticareas(convexity)andinthedistalandproximal
aorta than in the concave aortic sites in all patients. In
contrast, MMP-2 and TIMP-3 levels were elevated in the
concave sites.
Comparison of the distal, convex, and proximal aortic
sites revealed no signiﬁcant diﬀerences among BAV patients.
However, among TAV patients, TIMP-3 levels were higher in
the concave sites than in the convex, distal, and proximal
aortic sites. Comparisons between the proximal and distal
aortic sites revealed an elevated TIMP-4 concentration in
the distal aorta of TAV patients. Signiﬁcantly higher TIMP-
3 levels were revealed in four aortic sites of BAV patients
(n = 19)thaninthoseofTAVpatients(n = 7).Furthermore,
MMP-2, TIMP-2, TIMP-3, and TIMP-4 concentrations were
also much higher in the proximal aorta of BAV patients than
in that of TAV patients.
Patients were categorized into two groups on the basis
of their age. Because of the signiﬁcantly older age of TAV
patients, 51 years was considered the age threshold. Conse-
quently, all TAV patients were placed in the group aged >51
years.
Within the BAV group, patients aged ≤51 years had
signiﬁcantly lower TIMP-3 expression in the distal and con-
vex aortic sites than in the concavesite. Comparison between
the aneurysmal areas (distal, convex, and proximal aortic
sites) revealed increased levels of MMP-8 and TIMP-4 in
the distal aorta than those in the proximal aorta. Sig-
nificantly elevated MMP-8 and MMP-9 levels were also de-
tected among BAV patients aged ≥52 years in the concavity
compared with younger patients.
To classify patients on the basis of the aortic aneurysm
diameter, a threshold between 54 and 55mm was chosen;
all TAV patients were allocated to the group with aneurysms
≥55mm.6 The Scientiﬁc World Journal
Higher MMP-8 and MMP-9 levels were detected in the
convex aortic sites than in the concave aortic sites of BAV
patients with aneurysms ≤54mm in diameter. In contrast,
TIMP-3 and TIMP-4 levels were signiﬁcantly lower in the
convex aortic sites.
MMP-8 and MMP-9 levels were also elevated in the
distal aorta compared with those in the concave aortic sites,
but TIMP-3 levels were elevated in the concave sites when
compared with the distal and proximal aortic sites.
Patients with BAV and aneurysms ≥55mm in diameter
had considerably higher levels of MMP-8 and MMP-9 in the
convex sites than in the concave sites.
ElevatedMMP-8levelsweredetectedintheproximaland
distal aortic sites than in the concave sites; TIMP-3 levels
were higher in the proximal aorta than in the distal aorta.
The TAV group had higher TIMP-3 expression in the
concave sites than in the convex sites.
Analysis of the male BAV group revealed signiﬁcantly
increased MMP-8 and MMP-9 levels in the dilated convex
sites than in the concave sites, which had elevated TIMP-
3 levels. Among female BAV patients, the distal and the
proximal aortic sites had elevated MMP-8 and MMP-9 levels
compared with those in the concave sites, whereas TIMP-3
levels were lower in the former sites. Comparison between
the male BAV groups revealed elevated TIMP-3 levels in the
convex sites than in the distal aortic sites. Among the male
TAV group, comparisons between the distal, convex, and
proximal sites did not reveal any signiﬁcant diﬀerences.
The BAV group with aortic valve insuﬃciency had
elevated TIMP-3 levels in the convex aortic sites than in
the concave aortic sites. In contrast to TAV patients with
aorticvalveinsuﬃciency,BAVpatientswithinsuﬃciencyhad
increased TIMP-3 concentrations in the convex aortic sites.
The BAV group with a combination of aortic valve dis-
eases had signiﬁcantly increased MMP-8 and MMP-9 levels
in the convex aortic sites. TIMP-3 levels, on the other hand,
were higher in the convex aortic sites than in the distal aorta.
Of note, some studies did not observe diﬀerences in gene
expression of MMPs and TIMPs between patients with BAV
and TAV [13, 14]. Therefore, we listed the limitations of
our study as follows: we were unable to collect appropriate
control samples, especially those samples of nonaneurysmal
andwithexcludingatheroscleroticaortas.Inaddition,wedid
not detect signiﬁcant correlation between the histopatholog-
ical features and elevation of MMPs and TIMPs (data not
shown). However, we believe that this study clearly reﬂected
the diﬀerence in the elevation of MMPs and TIMPs protein
levels in tissue of thoracic ascending aneurysms of patients
with BAV and TAV.
5. Conclusions
Although we did not measure these proteins in blood or
body liquids, the obtained results indicate that MMPs and
matrixproteinscanvaryinconcentrationinascendingaortic
aneurysms in patients with BAV. Many studies support a
genetic origin of BAV [15–19]; however, hemodynamics can
also play a role in the pathogenesis of BAV and/or ascending
aortic aneurysms. Recent studies have indicated that aortic
wall shear stress diﬀers locally between BAV and control pa-
tients when examined by magnetic resonance imaging [20,
21]. Therefore, we believe that simultaneous detection of
MMPs and TIMPs oﬀers a powerful tool for systematic in-
vestigations to further our understanding of the complex
pathogenesis of thoracic aortic aneurysms.
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